Glenmark Pharma gets USFDA approval for generic version of Mylan’s anti-inflammation ointment

Glenmark Pharmaceuticals said it has got the US FDA approval to sell the generic version of corticosteroid ointment Kenalog from Mylan Pharmaceuticals.

The primary ingredient is triamcinolone, a corticosteroid that reduces the actions of chemicals in the body that cause inflammation.

Kenalog Ointment has annual sales of approximately $26.3 million in the US.

Glenmark said its current portfolio consists of 122 products authorized for distribution in the U.S. marketplace and 64 ANDA’s pending approval with the U.S. FDA.

Glenmark Pharmaceuticals is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue. It said it has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.

The company has significant presence in the branded generics markets across emerging economies including India, and operates 16 manufacturing facilities across five countries, besides six R&D centers.

The Generics business of Glenmark services the requirements of the US and Western European markets. The API or active pharmaceutical ingredients business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.